Search
Maravai LifeSciences Holdings Inc
MRVIAdd to Watchlist
4.325USD
-0.045-1.03%
Market hours （ET）Quotes delayed by 15 min
637.92MMarket Cap
LossP/E TTM
More Details of Maravai LifeSciences Holdings Inc Company
Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
Maravai LifeSciences Holdings Inc Info
Ticker SymbolMRVI
Company nameMaravai LifeSciences Holdings Inc
IPO dateNov 20, 2020
CEOBrust (Bernd)
Number of employees570
Security typeOrdinary Share
Fiscal year-endNov 20
Address10770 Wateridge Circle Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18585460004
Websitehttps://www.maravai.com/
Ticker SymbolMRVI
IPO dateNov 20, 2020
CEOBrust (Bernd)
Company Executives of Maravai LifeSciences Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
429.95K
+27.80%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+63.27%
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
316.63K
-28.85%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
264.91K
+33.65%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
169.91K
--
Mr. Luke Joseph Marker
Mr. Luke Joseph Marker
Director
Director
138.06K
--
Mr. Constantine S. (Dean) Mihas
Mr. Constantine S. (Dean) Mihas
Director
Director
--
--
Mr. Sean L. Cunningham
Mr. Sean L. Cunningham
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Bernd Brust
Mr. Bernd Brust
Chief Executive Officer, Director
Chief Executive Officer, Director
2.00M
--
Mr. Rajesh J. (Raj) Asarpota
Mr. Rajesh J. (Raj) Asarpota
Chief Financial Officer
Chief Financial Officer
500.00K
--
Ms. Christine Dolan
Ms. Christine Dolan
Executive Vice President, General Manager - Cygnus Technologies
Executive Vice President, General Manager - Cygnus Technologies
429.95K
+27.80%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Chairman of the Board
Independent Chairman of the Board
365.89K
+63.27%
Mr. Kurt Oreshack
Mr. Kurt Oreshack
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
316.63K
-28.85%
Mr. Gregory T. (Greg) Lucier
Mr. Gregory T. (Greg) Lucier
Independent Director
Independent Director
264.91K
+33.65%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
North America
112.38M
60.50%
Asia Pacific
41.47M
22.33%
Europe, the Middle East and Africa
30.92M
16.65%
Latin and Central America
971.00K
0.52%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 15 hours ago
Updated: 15 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GTCR Golder Rauner, LLC
13.66%
12 West Capital Management, L.P.
6.05%
Braidwell LP
5.66%
Hudson View Capital LLC
5.41%
BlackRock Institutional Trust Company, N.A.
5.38%
Other
63.84%
Shareholders
Shareholders
Proportion
GTCR Golder Rauner, LLC
13.66%
12 West Capital Management, L.P.
6.05%
Braidwell LP
5.66%
Hudson View Capital LLC
5.41%
BlackRock Institutional Trust Company, N.A.
5.38%
Other
63.84%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.84%
Hedge Fund
24.12%
Investment Advisor/Hedge Fund
17.84%
Private Equity
13.66%
Individual Investor
6.46%
Corporation
5.41%
Research Firm
4.69%
Pension Fund
0.20%
Bank and Trust
0.12%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
476
140.69M
95.39%
-29.12M
2025Q4
498
130.99M
90.33%
-38.49M
2025Q3
518
128.65M
88.93%
-44.43M
2025Q2
560
144.27M
100.21%
-25.80M
2025Q1
589
133.65M
92.84%
-44.45M
2024Q4
580
144.56M
101.93%
-33.57M
2024Q3
603
148.21M
104.79%
-33.05M
2024Q2
611
152.09M
114.44%
-19.50M
2024Q1
609
139.87M
105.40%
-26.88M
2023Q4
621
137.21M
103.78%
-26.31M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GTCR Golder Rauner, LLC
20.15M
13.77%
--
--
Dec 31, 2025
12 West Capital Management, L.P.
8.92M
6.09%
-3.60M
-28.75%
Dec 31, 2025
Braidwell LP
8.35M
5.71%
--
--
Dec 31, 2025
Hudson View Capital LLC
7.98M
5.45%
-961.72K
-10.76%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
7.94M
5.42%
+248.40K
+3.23%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
6.34M
4.33%
+178.44K
+2.90%
Dec 31, 2025
Mackenzie Financial Corporation
6.17M
4.22%
+104.36K
+1.72%
Dec 31, 2025
Renaissance Technologies LLC
4.23M
2.89%
-93.00K
-2.15%
Dec 31, 2025
Tejara Capital Ltd.
3.02M
2.06%
+566.77K
+23.10%
Dec 31, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
Global X Genomics & Biotechnology ETF
0.41%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
View more
Global X Genomics & Biotechnology ETF
Proportion0.41%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
